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Erythrokeratodermia variabilis (EKV) is an autosomal dominant keratinization disorder characterized by migratory
erythematous lesions and fixed keratotic plaques. All families with EKV show mapping to chromosome 1p34-p35,
and mutations in the gene for connexin 31 (Cx31) have been reported in some but not all families. We studied
eight affected and three healthy subjects in an Israeli family, of Kurdish origin, with EKV. After having mapped
the disorder to chromosome 1p34-p35, we found no mutations in the genes for Cx31, Cx31.1, and Cx37. Further
investigation revealed a heterozygous TrC transition leading to the missense mutation (F137L) in the human gene
for Cx30.3 that colocalizes on chromosome 1p34-p35. This nucleotide change cosegregated with the disease and
was not found in 200 alleles from normal individuals. This mutation concerns a highly conserved phenylalanine,
in the third transmembrane region of the Cx30.3 molecule, known to be implicated in the wall formation of the
gap-junction pore. Our results show that mutations in the gene for Cx30.3 can be causally involved in EKV and
point to genetic heterogeneity of this disorder. Furthermore, we suggest that our family presents a new type of
EKV because of the hitherto unreported association with erythema gyratum repens.
Connexins (denoted by the prefix “Cx”) are a family of
polypeptides that form the subunits of the gap-junction
channels. Members of the connexin family are charac-
terized by four hydrophobic transmembrane domains
(M1–M4) that are linked by one cytoplasmic and two
extracellular (E1 and E2) loops. The N and C termini
are located on the cytoplasmic membrane face. Extra-
cellular-loop and transmembrane domains display the
highest homology between the connexin family mem-
bers, whereas the cytoplasmic loop and the C-terminal
region are highly variable. Six connexin polypeptides
assemble into a connexon, a hemichannel that interacts
with its counterpart on adjacent cells to form a complete
intercellular channel, thereby connecting the cytoplasm
of neighboring cells (Yeager and Nicholson 1996). Gap
junctions are composed of numerous aggregated con-
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nexons. Functionally, gap junctions allow rapid transfer,
between adjacent cells, of ions and second messenger
molecules of size !1 kD, thereby permitting a coordi-
nated response of groups of cells to external stimuli. This
cell-cell communication is crucial for growth control and
differentiation, as well as for maintenance of tissue ho-
meostasis (Goodenough et al. 1996). Signal transmission
via gap junction is modulated by a number of molecular
and physiological conditions. Channel permeability and
voltage-gating properties depend on the composition of
the connexons. So far, 114 connexin genes have been
described, and each tissue expresses a specific subset of
it. The importance of the physiological functions of con-
nexins is illustrated by the identification of connexin
mutations as the molecular cause of different human
diseases (Krutovskikh and Yamasaki 2000). These re-
sults from human diseases are further corroborated by
the findings obtained in knockout mice (White and Paul
1999).
Erythrokeratodermia variabilis (EKV [MIM 133200])
is a rare, autosomal dominant genodermatosis charac-
terized by the coexistence of twomorphological features:
usually transient areas of erythema and keratotic lesions
that are more or less fixed. The erythematous patches
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Figure 1 Pedigree and haplotype analysis of the family with EKV. Haplotypes are given (top to bottom) for markers D1S496, D1S472,
and D1S186. Haplotype 1-5-4 was found to segregate with the disease. x p meiotic recombination.
vary in size, shape, and location and seem to be pro-
voked by exposure to wind, cold, heat, and emotional
stress (Rappaport et al. 1986). There are also fixed
brownish-red hyperkeratotic plaques—particularly over
the knees, elbows, groin, and axillae—in a symmetric
distribution. There is a high intra- and interfamilial var-
iability of the phenotype. Generally, EKV presents at
birth or begins during early life. All families with EKV
so far have shown mapping to chromosome 1p34-35,
between the markers D1S496 and D1S186, with a max-
imum LOD score (Zmax) of 12.88 for D1S472 (Richard
et al. 1997). These markers define a 2.6-cM candidate
interval that contains a cluster of three genes for Cx:
GJB3, encoding Cx31, GJA4, encoding Cx37, and
GJB5, encoding Cx31.1 (van der Schroeff et al. 1988;
Richard et al. 1997). Subsequently, six distinct Cx31
mutations were found—but only in 8 of 20 EKV families
investigated, suggesting that EKV is genetically hetero-
geneous (Richard et al. 1998, 2000;Wilgoss et al. 1999).
The human candidate region is orthologous to mouse
chromosome 4, which harbors, in addition to the three
genes described above, the gene for Cx30.3 (Hennemann
et al. 1992). This suggests that this gene, GJB4, may be
a good candidate. In this report, we describe an Israeli
family, of Kurdish origin, with EKV, which we have also
mapped to chromosome 1p34-35. Although we found
no mutations in genes for Cx31, Cx31.1, and Cx37, we
detected one, F137L, in the gene for Cx30.3. These find-
ings provide the first and clear evidence for the causal
involvement of a second connexin gene in this disorder
and may delineate a specific subset.
An Israeli family of Kurdish origin that had already
been described in 1978 (Hacham-Zadeh and Even-Paz
1978) was the object of our study. The pedigree included
32 individuals in four generations, of whom 8 affected
and 3 healthy subjects were available for study (fig. 1).
The dermatosis started at birth or shortly thereafter, and
the patients were usually in good general health. Mi-
gratory erythematous lesions tended to gradually turn
into more or less fixed keratotic plaques. Some of these
erythematous lesions appeared as erythema gyratum re-
pens, characterized by rapidly migrating figurate ery-
thema 1–2 cm wide in an annular, garland, or spiral
arrangement (Braun-Falco et al. 1984), which so far has
not been reported in EKV (fig.2B and C). Generally, the
palms and soles were intact. Lesions tended to become
worse in summer and to improve in winter. In one of
the patients, lesions also worsened during her pregnan-
cies (fig. 2). Audiograms in two affected patients (III-6
and IV-1) were normal.
To see whether EKV in this family also shows linkage
to 1p34-p35, as described elsewhere (Richard et al.
1997), linkage analysis with the three Ge´ne´thon micro-
satellite markers D1S186, D1S496, and D1S472 was
performed (Dib et al. 1996). The Zmax (2.343, at recom-
bination fraction 0) of the two-point analyses, when
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Figure 2 Clinical pictures. A, III-6, a 37-year-old man. The nape of the neck has brownish, lichenification-like hyperkeratotic plaque with
mostly clear-cut borders. B, IV-1, a 19-year-old man. The periaxillary region has well-demarcated polycyclic plaque composed of diffuse scaling
and erythema gyratum repens–like migratory lesions. C, IV-2, a 9.5-year-old girl. The anterior trunk has erythema gyratum repens–likemigratory
lesions.
MLINK from the LINKAGE 5.2 package (Lathrop et
al. 1984) is used, was obtained with marker D1S472,
and all affected individuals shared a common allele (fig.
1). The coding region of the genes for Cx37 (GJA4) and
Cx31 (GJB3) were amplified as described elsewhere (Ri-
chard et al. 1997, 1998). The gene for Cx31.1 (GJB5)
was amplified using primers Cx31.1-F (5′-AGAGCA-
AGTCTGTGATAAATGTAGG-3′) and Cx31.1-R (5′-
CCCCTACCTCATGGCTTAGC-3′). Sequence analysis
of the genes for Cx31 and Cx31.1 did not reveal any
pathogenic mutation in two patients (II-1 and III-8) and
one unaffected individual (II-5) in the family with EKV.
In one patient (III-2), we identified, at position 388 of
the gene for Cx37, a GrA transition that abolishes a
BsiEI restriction site. However, this previously reported
polymorphism (Val130Ile) (Krutovskikh et al. 1996) did
not cosegregate with the disease in the kindredwith EKV,
thus excluding the possibility that the disease is caused
by this nucleotide change.
Mouse Cx30.3 transcripts are strongly expressed in
keratinocytes, and the gene is localized within the con-
nexin cluster on mouse chromosome 4 (Hennemann et
al. 1992; Schwarz et al. 1992). This region is ortholo-
gous to human 1p34-p35, suggesting that the gene for
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Figure 4 Molecular analysis of the gene for Cx30.3 (GJB4) in
the family with EKV. A and B, Chromatograms of an affected indi-
vidual with the Cx30.3 mutation, T409C, and a normal individual.
C, Inheritance of the T409C mutation by restriction-enzyme digestion
with SmlI. Normal alleles produce a 904-bp band that is cleaved into
488- and 416-bp fragments in mutant alleles. Lanes 1–10, Individuals
II-1, II-5, III-1, III-2, III-3, III-5, III-6, III-8, III-9, and IV-1, respectively
(see pedigree in fig. 1).
Figure 3 Expression analysis of the Cx30.3 transcript. Lanes
1–4, RT-PCR with Cx30.3 primers. Lanes 5–8, PCR with Cx30.3
primers, omitting RT. Lanes 9–12, RT-PCR with actin primers. Total
RNA for the reactions was derived from human skin biopsy (lanes 1,
5, and 9), cultured keratinocytes (lanes 2, 6, and 10), cultured skin
fibroblasts (lanes 3, 7, and 11), and peripheral leukocytes (lanes 4, 8,
and 12).
Cx30.3 might be a candidate in some cases of EKV.
Searching the nonredundant database by BLASTN, at
the UKHuman GenomeMapping Project ResourceCen-
tre Web site, with the mouse gene for Cx30.3 (GenBank
accession number M91443), we identified the human
PAC clone RP1-34M23 (GenBank accession number
AL121988), which contains the four genes for Cx—
Cx31, Cx31.1, Cx37, and Cx30.3. Expression analysis
by reverse transcription (RT)–PCR showed that the gene
for Cx30.3 is indeed expressed both in human skin in
vivo and in cultured epidermal keratinocytes but not in
cultured skin fibroblasts and leukocytes (fig. 3). There-
fore, a 952-bp fragment containing the entire coding
region of the gene for Cx30.3 was amplified using prim-
ers Cx30.3-F (5′-CAATCGCACCAGCATTAAGGG-3′;
nt 126 to 106) and Cx30.3-R (5′-TGATCTTAT-
CTGCTGATCTCGCAG-3′; nt 803–826) in one affected
individual (III-2) in the family with EKV. Sequence anal-
ysis detected a heterozygous TrC nucleotide transver-
sion at position 409, resulting in a phenylalanine-to-
leucine change at position 137 (F137L) (fig. 4A and B).
This heterozygous missense mutation, which creates a
new SmlI restriction site, was found only in affected
individuals in this family and was not detected in either
unaffected family members (fig. 4C) or 200 alleles from
normal white individuals. Sequence analysis of the gene
for Cx30.3 did not reveal any other nucleotide variations
in 10 control alleles.
This mutation occurs within the third transmembrane
domain, M3, of Cx30.3 and alters a phenylalanine res-
idue that is highly conserved within the Cx family of
proteins (fig. 5). The same mutation was previously re-
ported in the homologous residue of the gene for Cx32
(residue F141L) in X-linked Charcot-Marie-Tooth dis-
ease (Rouger et al. 1997) and of the gene for Cx31
(residue F137L) in a sporadic case of severe EKV (Ri-
chard et al. 2000), providing evidence for the crucial
function of this amino acid residue. Indeed, the M3 do-
main is known to be involved in the formation of the
wall of the gap-junction pore and is at least partly im-
plicated in the voltage gating of the channels. Closure
of the channel occurs by the tilt of theM3 domain, which
blocks the channel by moving small polar groups out of
the lumen and permitting bulky phenylalanines into it
(Bennett et al. 1991). It has been proposed that the ki-
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Figure 5 Sequence alignment of the M3 and partial E2 domains of human Cx30.3 with other b-class gap-junction proteins. The arrowhead
indicates the position of the Cx30.3 mutation, F137L, in the family with EKV. GenBank accession numbers are CAB90270 (for hCx30.3),
AAA37428 (for mCx30.3), CAA53762 (for rCx30.3), CAA06165 (for hCx31), AAD18005 (for hCx31.1), NP_003995 (for hCx26), B29005
(for hCx32), and NP_006774 (for hCx30). The sequence of pCx30.3 was obtained from Itahana et al. (1996). h p human, m p mouse, rp
rat, and p p porcine.
netics of channel closure in response to voltage changes
is inversely correlated with the number of phenylalanines
in the M3 domain. Cx32 and Cx26, which harbor three
phenylalanines, display slower kinetics than do Cx37
and Cx40, which have only one phenylalanine each.
Cx30.3, with two phenylalanines, should have, accord-
ing to this model, an intermediate channel-closure time
(Unwin 1989; Hennemann et al. 1992). Hence, replace-
ment of phenylalanine 137 by leucine may lead to faster
closure of the channel, inhibiting the propagation of sig-
nals important for normal epidermal growth and dif-
ferentiation. Two other mutations in the vicinity of
Phe137, I141V and a deletion of Ile141, were identified
in the M3 domain of Cx31 in recessive nonsyndromic
hearing loss (Liu et al. 2000; Richard et al. 2000). Thus,
mutations within the M3 domain may produce different
phenotypes, such as hearing or skin disorders. This is
not surprising, since Cx30.3 mRNA expression is re-
stricted to skin and kidney in rodents, whereas the gene
for Cx31 (GJB3) is also expressed in the inner ear and
in the CNS (Hoh et al. 1991; Hennemann et al. 1992;
Tucker and Barajas 1994).
The similarity in clinical pictures of patients with EKV
who have mutations in the genes for Cx31 and Cx30.3
suggests that these two connexins are functional partners
in the formation of keratinocyte gap junctions. Never-
theless, the cutaneous phenotype of EKV with erythema
gyratum repens without palmoplantar involvement,
which was observed in some patients from the family
that we studied, may define a specific clinical subset and
indicate subtle molecular and biological differences.Our
results show that the connexin protein Cx30.3 is im-
portant for both the regulation of epidermal differen-
tiation and the maintenance of epidermal homeostasis.
Further investigations will be necessary to elucidate the
specific role that each of the epidermally expressed con-
nexins plays in the physiology and pathophysiology of
epidermal tissues and in the clinical phenotype of con-
nexin mutants.
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